Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › CORONA

CORONA

CORONA Remedies Limited
Micro-capPharma ↗

What the six lenses say about CORONA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2071.4
2026-09-08
VWAP · 1Y anchor
₹1502
+37.9% from VWAP
P/E · TTM
68.5×
TTM EPS ₹30.3
52-week range
88%
position low→high
RSI(14)
48
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How CORONA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
4.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD553›

The actual numbers

Price vs VWAP (1y)+37.9%
Price vs 50-EMA+1.7%
RSI(14)48
RS vs Nifty 500 · 3M+14.6%
RS vs sector · 3M+8.5%
52-week range88%
Volume vs 30d avg0.29×
Volume vs 60d avg0.25×
ATR(14) · volatility66.8
Bollinger width · vol contraction0.067
FundamentalD962›

The actual numbers

Return on equity (ROE)24.6%
Operating margin17.7%
Net margin13.1%
Debt / equity0.22×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)68.5×
TTM EPS₹30.3
52-week range88%
CatalystD741›

The actual numbers

Earnings & momentum36
Capital actions30
Governance81

Every filing in the corporate-announcements panel below.

FlowD342›

The actual numbers

Promoter holding69.0%
Delivery · 30d avg52.6%
Up/down-day asymmetry-3.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D5 + D3 ) ÷ 2 = 4.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Medium
51
Conviction score 51/100 · avg-decile strength 4.0/10
Conviction score51/100›
TechnicalD5›
FundamentalD9›
ValuationD1›
CatalystD7›
FlowD3›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.9pp
+2.3pp
+4.7pp
+16.2pp
+33.7pp
—
Nifty 500
Broad-market baseline
-0.9pp
+2.3pp
+3.7pp
+14.6pp
+28.0pp
—
Sector
Own-sector index
—
—
+0.8pp
+8.5pp
+14.9pp
—

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

CORONA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2071.40-28.70

Relative strength

RS vs baseline · rebased to 100

CORONA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
147.55-1.41

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricSep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)314298294347361342353
↳ change QoQ—-5.1%-1.3%+18.0%+4.0%-5.3%+3.2%
EBITDA (₹cr)67695470788362
EBITDA margin21.3%23.2%18.4%20.2%21.6%24.3%17.6%
PAT (₹cr)43453246524145
↳ change QoQ—+4.7%-28.9%+43.8%+13.0%-21.2%+9.8%
Net margin13.7%15.1%10.9%13.3%14.4%12.0%12.8%
EPS (₹)7.037.355.167.558.556.757.41
D/E———————
YoY growth · Mar '26Revenue +20.1% YoYPAT +40.6% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 9 Sep '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 9 Sep '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 30 Jun '26
    LOWgovernance
    Commencement of commercial production/operations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds CORONA

Mutual funds holding CORONA (10)

FundWeightAUM ₹crGrade
Invesco India Mid Cap Gr1.00%14,721
Aditya BSL ELSS Tax Saver Gr LSP0.66%14,660
Aditya BSL ELSS Tax Saver Gr0.66%14,660
Invesco India Smallcap Reg Gr2.03%14,475
Invesco India large& mid cap Gr0.96%11,746
Invesco India Multicap Gr1.33%4,398
WhiteOak Capital Multi Cap Reg Gr0.51%4,134
HDFC Pharma and Healthcare Reg Gr1.24%2,940
Invesco India ELSS Tax Saver Fund Gr0.75%2,699
Union Flexi Cap Gr0.61%2,404

ETFs holding CORONA (0)

No tracked ETF holds CORONA ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma